OBJECTIVES: Barrett's oesophagus is a pre-neoplastic lesion, which develops as a complication of chronic gastro-oesophageal reflux disease and predisposes the patient to oesophageal adenocarcinoma. Our aim was to characterize karyotypic changes that may occur during the progression of Barrett's metaplasia through low-grade dysplasia and high-grade dysplasia to adenocarcinoma. METHODS: The technique of comparative genomic hybridization was used to characterize genome-wide changes in biopsies from patients with low-grade dysplasia, low-grade dysplasia plus high-grade dysplasia, high-grade dysplasia or adenocarcinoma. Both fresh and archival material was examined. RESULTS: Comparative genomic hybridization revealed a large amount of widespread chromosome instability at the high-grade dysplasia stage. No significant chromosome changes were detectable by comparative genomic hybridization in patients with low-grade dysplasia. Karyotypic changes in the adenocarcinoma patients were more specific than those found in the high-grade dysplasia patients. Chromosome 4 was amplified most often in high-grade dysplasia and chromosome 8q was amplified most frequently in the adenocarcinomas. CONCLUSIONS: These data demonstrate that high-grade dysplasia is the stage exhibiting widespread chromosome instability, which is detectable by comparative genomic hybridization. This instability is undetectable in low-grade dysplasia. The chromosome variation seen at high-grade dysplasia may be the source of more specific karyotypes that progress to adenocarcinoma. Importantly, we have identified chromosome 4 amplification as being heavily involved in the initiation of Barrett's progression. Specific chromosome changes (4 and 8q) may represent important regions on which to focus attention in future studies, with a view to identifying diagnostic markers.
OBJECTIVES: Barrett's oesophagus is a pre-neoplastic lesion, which develops as a complication of chronic gastro-oesophageal reflux disease and predisposes the patient to oesophageal adenocarcinoma. Our aim was to characterize karyotypic changes that may occur during the progression of Barrett's metaplasia through low-grade dysplasia and high-grade dysplasia to adenocarcinoma. METHODS: The technique of comparative genomic hybridization was used to characterize genome-wide changes in biopsies from patients with low-grade dysplasia, low-grade dysplasia plus high-grade dysplasia, high-grade dysplasia or adenocarcinoma. Both fresh and archival material was examined. RESULTS: Comparative genomic hybridization revealed a large amount of widespread chromosome instability at the high-grade dysplasia stage. No significant chromosome changes were detectable by comparative genomic hybridization in patients with low-grade dysplasia. Karyotypic changes in the adenocarcinomapatients were more specific than those found in the high-grade dysplasiapatients. Chromosome 4 was amplified most often in high-grade dysplasia and chromosome 8q was amplified most frequently in the adenocarcinomas. CONCLUSIONS: These data demonstrate that high-grade dysplasia is the stage exhibiting widespread chromosome instability, which is detectable by comparative genomic hybridization. This instability is undetectable in low-grade dysplasia. The chromosome variation seen at high-grade dysplasia may be the source of more specific karyotypes that progress to adenocarcinoma. Importantly, we have identified chromosome 4 amplification as being heavily involved in the initiation of Barrett's progression. Specific chromosome changes (4 and 8q) may represent important regions on which to focus attention in future studies, with a view to identifying diagnostic markers.
Authors: S H Doak; G J S Jenkins; E M Parry; F R D'Souza; A P Griffiths; N Toffazal; V Shah; J N Baxter; J M Parry Journal: Gut Date: 2003-05 Impact factor: 23.059
Authors: Shannon M Brankley; Kenneth K Wang; Aaron R Harwood; Dylan V Miller; Mona S Legator; Lori S Lutzke; Benjamin R Kipp; Larry E Morrison; Kevin C Halling Journal: J Mol Diagn Date: 2006-05 Impact factor: 5.568
Authors: William W Lockwood; Kelsie L Thu; Lin Lin; Larissa A Pikor; Raj Chari; Wan L Lam; David G Beer Journal: Clin Cancer Res Date: 2012-02-10 Impact factor: 12.531
Authors: Xiaohong Li; Patricia C Galipeau; Carissa A Sanchez; Patricia L Blount; Carlo C Maley; Jessica Arnaudo; Daniel A Peiffer; Dmitry Pokholok; Kevin L Gunderson; Brian J Reid Journal: Cancer Prev Res (Phila) Date: 2008-11
Authors: Thomas G Paulson; Carlo C Maley; Xiaohong Li; Hongzhe Li; Carissa A Sanchez; Dennis L Chao; Robert D Odze; Thomas L Vaughan; Patricia L Blount; Brian J Reid Journal: Clin Cancer Res Date: 2009-05-05 Impact factor: 12.531
Authors: J Pal; R Bertheau; L Buon; A Qazi; R B Batchu; S Bandyopadhyay; R Ali-Fehmi; D G Beer; D W Weaver; R J Shmookler Reis; R K Goyal; Q Huang; N C Munshi; M A Shammas Journal: Oncogene Date: 2011-03-21 Impact factor: 9.867